Combination of Extracorporeal Life Support and Mesechymal Stem Cell Therapy for Treatment of ARDS in Combat Casualties and Evacuation if Service Members with ARDS
Technical Report,30 Sep 2017,29 Sep 2018
University of Pittsburgh Pittsburgh United States
Pagination or Media Count:
Transfer of injured service members from the Level 3 combat support hospital to level 4 and 5medical facility increases their chance of survival from devastating injuries. Aeromedical evacuation of patients with Acute Respiratory Distress Syndrome ARDS is sometimes beyond the possibilities because of limitations providing ventilator support in flight with a possible further deterioration in patient status. Cell based therapy with adult bone marrow-derived mesenchymal stromal cells B-MSC in experimental models of ARDS has been the focus of intense investigation. Data suggest that administered allogeneic B-MSCs can mitigate hypoxemia in ARDS and promote recovery. However, it is unknown how this new form of therapy can be used as an adjunct to current supportive measures for lung failure. Our objective is to complete a series of preclinical studies in large animal models using extracorporeal membrane oxygenation ECMO alone or in combination with B-MSC in sheep and pigs with two different models of ARDS.
- Medicine and Medical Research